LOTTE Biologics Receives 2026 CDMO Leadership Awards,

Recognized as Best New or Relaunched CDMO

Seoul, South Korea, March 26, 2026 - LOTTE Biologics (Co-CEOs James Park and Shin Yooyeol) announced that it had received an award at the 2026 CDMO Leadership Awards, one of the most prestigious recognitions in the global contract development and manufacturing organization (CDMO) industry.

The CDMO Leadership Awards, hosted by Outsourced Pharma and Life Science Connect, recognize CDMOs that have demonstrated outstanding performance over the past 24 months based on evaluations from industry professionals across key criteria, including capabilities, compatibility, expertise, quality, reliability, and service.

The awards are well recognized internationally for their credibility and objectivity through the inclusion of an independent evaluation conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD). With companies being nominated by clients or industry peers only, the program is independent of marketing, advertising or sponsorships and is based on research data and expert judges.

LOTTE Biologics was selected as a recipient in the “Best New or Relaunched CDMO” category, which recognizes companies that have successfully entered or redefined the CDMO market through clear strategic direction, differentiated capabilities, and strong competitive positioning, earning high levels of trust from global partners.

The company noted that the award reflects the rapid expansion of its brand recognition in the global market within just four years of launch, as well as direct recognition from customers for its quality and execution capabilities.

Industry observers have highlighted LOTTE Biologics’ dual-site strategy as a key driver behind its recognition, supported by experience with over 62 global regulatory approvals and expanding ADC (antibody-drug conjugate) capabilities. These strengths have contributed to strong customer confidence and positive market perception.

Building on the upcoming completion of its Songdo Bio Campus, LOTTE Biologics continues to expand its portfolio from monoclonal antibodies to ADCs, reinforcing its position as a key player in the next-generation biopharmaceutical market.

A company representative stated,

“This award is especially meaningful as it reflects recognition earned within a short period of time in the global CDMO market. We will continue to strengthen our role and responsibility as a partner that delivers tangible value to the global biopharma ecosystem, beyond simple growth.”

Meanwhile, during DCAT Week, LOTTE Biologics is hosting private meetings at the Lotte New York Palace Hotel, engaging in active business discussions to expand strategic partnerships with global pharmaceutical and biotech companies.